XomaXOMA
XOMA
About: XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Employees: 13
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0.82% less ownership
Funds ownership: 66.36% [Q4 2024] → 65.54% (-0.82%) [Q1 2025]
2% less funds holding
Funds holding: 65 [Q4 2024] → 64 (-1) [Q1 2025]
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
24% less capital invested
Capital invested by funds: $205M [Q4 2024] → $156M (-$48.4M) [Q1 2025]
83% less call options, than puts
Call options by funds: $4K | Put options by funds: $24K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$35
29%
upside
Avg. target
$70
156%
upside
High target
$104
283%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 283%upside $104 | Buy Reiterated | 28 May 2025 |
Benchmark Robert Wasserman | 29%upside $35 | Buy Initiated | 17 Apr 2025 |
Financial journalist opinion
Based on 4 articles about XOMA published over the past 30 days
Positive
Seeking Alpha
5 days ago
Collect Up To 11.5% From The Healthcare Sector
Make your portfolio income-producing and provide valuable cash for your daily life. Aim to be healthy and have the money you need when emergencies arise. America is getting older. Healthcare income opportunities abound.
Neutral
GlobeNewsWire
2 weeks ago
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA) and Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX) today announced that they have entered into a definitive merger agreement (“the Merger Agreement”), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock (“Turnstone common stock”) plus one non-transferable contingent value right (“CVR”).
Positive
Zacks Investment Research
2 weeks ago
XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?
XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Neutral
GlobeNewsWire
3 weeks ago
XOMA Royalty Declares Quarterly Preferred Stock Dividends
EMERYVILLE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
Neutral
GlobeNewsWire
1 month ago
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million.
Positive
Zacks Investment Research
1 month ago
XOMA Royalty (XOMA) Tops Q1 Earnings and Revenue Estimates
XOMA Royalty (XOMA) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.26 per share. This compares to loss of $0.86 per share a year ago.
Neutral
GlobeNewsWire
2 months ago
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025.
Neutral
GlobeNewsWire
2 months ago
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens
Neutral
Accesswire
3 months ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3
LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP).
Positive
Seeking Alpha
3 months ago
XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
XOMA aggregates future biotech royalties and milestone rights for stable, diversified revenue streams. However, I believe its preferred shares (under tickers XOMAO and XOMAP) offer attractive yields with cumulative, perpetual dividends. Since XOMA's diversified portfolio features high-potential, recently FDA-approved assets like Ojemda and Miplyffa, I also think the yields should be relatively secure.
Charts implemented using Lightweight Charts™